Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18655954 | 0.92 | CTSK (0.39) | CTSKBTKCA1CA2GAA | |
| SCHEMBL23763170 | 0.88 | CTSK (0.44) | CTSKBTKCA1CA2GAA | |
| SCHEMBL15246298 | 0.84 | CTSK (0.46) | CTSKBTKCA1CA2GAA | |
| SCHEMBL27172421 | 0.84 | CTSK (0.43) | CTSKBTKCA1CA2GAA | |
| SCHEMBL25497247 | 0.84 | EPHX1 (0.43) | CTSKBTKCA1CA2GAA | |
| SCHEMBL18655858 | 0.83 | CTSK (0.42) | CTSKBTKCA1CA2GAA | |
| SCHEMBL14669045 | 0.83 | BTK (0.49) | CTSKBTKCA1CA2GAA | |
| SCHEMBL30456955 | 0.83 | CTSK (0.39) | CTSKBTKCA1CA2GAA | |
| SCHEMBL26361721 | 0.81 | BTK (0.44) | CTSKBTKCA1CA2GAA | |
| SCHEMBL18616097 | 0.80 | BTK (0.46) | CTSKBTKCA1CA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| WO-2017045510-A1 | Β-LACTAMASE INHIBITOR AND APPLICATION THEREOF | 山东轩竹医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, ALPI | CTSK 1008/4885BTK 655/4885CA1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.